DFO for advanced HCC with impaired liver functio
- Conditions
- Chemoresistant HCC
- Registration Number
- JPRN-jRCTs061180032
- Lead Sponsor
- Sakaida Isao
- Brief Summary
Sorafenib which is recommended for the patients with reserved liver function, is often applied for the patients with deteriorated liver function, and entry of the patients did not progress. Furthermore, the newly molecular targeted agents made it difficult to continue this study. This is a too small number study to provide conclusions, and we describe only the results mentioned above.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 3
1) Patients with advanced hepatocellular carcinoma
2) Non-responders for chemotherapy with anticancer drugs
3) Patients who have no influence on previous treatment
4) Performance status(PS) 0 or 1
5) Child-Pugh B
6) Favorable function of major organs (bone marrow, kidney, heart), and meeting citeria as follows:
(1) WBC >= 2500/mm3
(2) platelet count>= 50000/mm3
(3) hemogrobin level >= 9.0g/dl
(4) total bilirubin <= 3.0mg/dl
(5) serum creatinine level < 2mg/dl
(6) BUN <= 25mg/dl
(7) prothrombin time activity >= 50%
7) age >= 20years, male and female
8)Patients provided written, informed consent to participate
1) Severe coexisting illness (expect for chronic hepatitis or liver cirrhosis)
2) Active double cancers
3) Past history of hypersensitivity for drugs including iodine and contrast agent
4) Patients with pregnancy, lactation or possibility of pregnancy
5) Past history of interstitial pneumonia
6) Chronic respiratory failure
7) Patients who judged as inadequacy due to other reasons by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Response, Progression-free survival, Safety